Summary
In order to devise a convenient and effective therapeutic regimen of intranasal salmon calcitonin (sCT) for the treatment of early postmenopausal bone loss, we studied the effects of a 1-year course of sCT nasal spray on vertebral mineral content (VMC), assessed by dual photon densitometry, and bone turnover in 21 early postmenopausal osteoporotic women. Subjects enrolled in the study had a value above the normal average of at least one index of bone turnover: whole body retention (WBR) of 99mTc-methylenedichloro-bisphosphonate (99mTc-MDP), serum bone gla protein (BGP), urinary hydroxyproline/creatinine excretion (HOP/Cr). After baseline evaluation, patients were randomized for treatment with either sCT (200 IU every other day) or plabebo. Treatment with sCT significantly increased VMC by 2.7±0.9% at 6 months, and 3.3±0.8% at 1 year, whereas a progressive decline was observed in the placebo group (-2.6±0.5%, and -3.5±0.5% after 6 and 12 months, respectively). These changes were associated with a progressive and significant reduction of all parameters of bone turnover in the sCT-treated patients, whereas no changes were detected in the control group during the study period. The differences between the two groups were significant after 1 year for VMC, BGP, and WBR (P<0.05, one-way analysis of variance). Thus, 200 IU intranasal sCT administered on alternate days is adequate to stop the fast bone loss occurring early after the menopause in women with high bone turnover rates. This therapeutical modality represents an important addition to the available pharmacologic spectrum for the prevention and treatment of postmenopausal osteoporosis.
Similar content being viewed by others
References
Gruber HE, Ivey JL, Baylink DJ, Matthews M, Nelp WB, Sisom K, Chesnut CH III (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metab Clin Exp 33:295–303
Gennari C, Chierichetti SM, Bigazzi S, Fusi L, Gonnelli S, Ferara R, Zacchei F (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464
Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8
McIntyre I, Stevenson JC, Whitehead MI, Wimalawansa SJ, Banks IM, Hanley MJR (1988) Calcitonin for prevention of postmenopausal bone loss. Lancet i:900–902
Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J Clin Invest 82:1268–1274
Reginster JY, Denis D, Albert A, Deroisy R, Lecart MP, Fontaine MA, Lembelin P, Franchimont P (1987) One-year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet ii:1481–1483
Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of salcatonin given intranasally on early postmenopausal bone loss. Br Med J 299:477–479
Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989). Nasal calcitonin for the treatment of established osteoporosis. Clin Endocrinol 30:435–442
Overgaard K, Hansen MA, Herss-Nielsen VA, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis: effect of withdrawal of treatment. Am J Med 89:1–6
Reginster JY, Denis D, Albert A, Franchimont P (1987) Assessment of the biological effectiveness of nasal synthetic salmon calcitonin (ssCT) by comparison with intramuscular (i.m.) or placebo injections in normal subjects. Bone Miner 2:133–140
Civitelli R, Agnusdei D, Nardi P, Zacchei P, Avioli LV, Gennari C (1988) Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption and 25-hydroxyvitamin D-1α-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 42:77–86
Slemenda CW, Hui SL, Longcope C, Johnston CC (1987) Sex steroids and bone mass. A study of changes about the time of menopause. J Clin Invest 80:1261–1269
Hui SL, Slemenda CW, Johnston CC, Appledorn CR (1987) Effects of age and menopause on vertebral bone density. Bone Miner 2:141–146
Yasumura S, Aloia JF, Gundberg CM, Yeh J, Vaswani AN, Yuen K, LoMonte AF, Ellis KJ, Cohn SH (1987) Serum osteocalcin and total body calcium in normal pre- and postmenopausal women and postmenopausal osteoporotic patients. J Clin Endocrinol Metab 64:681–685
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gennari, C., Agnusdei, D., Montagnani, M. et al. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. Calcif Tissue Int 50, 381–383 (1992). https://doi.org/10.1007/BF00301638
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00301638